INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Objective: to investigate the safety and immunogenicity of 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Subjects and methods. The investigation enrolled 30 patients with a reliable diagnosis of SLE; of them there were 27 women and 3 men at the age of 19 to 62 years. The disease duration ranged from 9 months to 20 years. At the time of inclusion in the investigation, the disease activity was high in 2 patients, moderate in 3, and low in 20; five patients were in remission. During a year before vaccination, pneumonia was detected in 5 (16.7%) of the 30 patients; there were a total of 18 episodes of various respiratory and ENT infections. The patients were examined at baseline and at 1, 3 and 12 months after vaccination. Standard clinical and laboratory studies and a detailed blood immunological analysis were carried out at visits. The levels of IgG antibodies to capsular polysaccharide pneumococcus were determined during each visit. Twenty-nine patients received glucocorticoids (GCs) at a dose of 5–30 mg/day; 24 – hydroxychloroquine; 14 – cytostatics (CS); 10 – biological agents (BAs) (5 – rituximab, 5 – belimumab). A single dose of 0.5 ml of PPV-23 (Pneumo 23, Aventis) was subcutaneously injected into the upper outer arm. Vaccination was done during the ongoing therapy with GC/CS and belimumab, as well as at least 1 month before the first (next) administration and/or 4.5–5 months after the last rituximab infusion. Results and discussion. 60% of patients were observed to have mild and moderate standard local vaccine reactions; 1 (3.3%) patient had a local hyperergic reaction eliminated within 7 days of the local application of antihistamines and GCs. During the follow-up, there was no SLE exacerbation significantly associated with the vaccination performed. No new autoimmune phenomena were found in any of the cases. A year after vaccination, a significant (2-fold or more) increase in anti-pneumococcal antibody levels remained in 19 (63.3%) patients (respondents); 36.7% of patients were nonrespondents. Among the patients who received a BA, the non-responders were significantly more than among those who did not take the drug (7 (70%) and 4 (20%), respectively) (p = 0.01). When treated with rituximab and belimumab, the number of non-respondents was comparable (4 and 3, respectively). The immunogenicity of PPV-23 was independent of the degree of SLE activity: the vaccine response was absent in 1 out of the 5 patients with high (n = 2) and medium (n = 3) SLE activities, as well as in 10 out of the 25 patients with low disease activity and remission. There was no development of considerable adverse reactions after vaccination in patients with high and medium SLE activity. The overall clinical efficiency of vaccination was 93.3%. Conclusion. Thus, PPV-23 shows a good tolerability and a sufficient immunogenicity in patients with SLE. There is a need for further investigations conducted in large samples of patients during long-term follow-ups in order to more fully evaluate the clinical efficacy, tolerability, and immunogenicity of PPV-23.

systemic lupus erythematosus, pneumonia, vaccination, 23-valent polysaccharide pneumococcal vaccine, immunosuppressive therapy, biological agents

1. Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Publ Health. 2007;38(3):528-36.

2. Levitsky A, Linder S, van Vollenhoven RF. Rituximab in the management of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice 2013;51(3):223-39 (In Russ.)]. doi: 10.14412/1995-4484-2013-1494

3. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10):3364-73. doi: 10.1002/art.34564

4. Gluck T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32(8):1473-80.

5. Reddy S, Wanchu A, Gupta V, Bambery P. Profile of opportunistic infections among patients on immunosuppressive medication. APLAR J Rheumatol. 2006;9:269-74. doi: 10.1111/j.1479-8077.2006.00212.x

6. Juarez M, Misischia R, Alarcon GA. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/ dermatomyositis. Rheum Dis Clin N Am. 2003;29:163-84. doi: 10.1016/S0889-857X(02)00100-X

7. Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61:409-13. doi: 10.1136/ard.61.5.409

8. Nossent J, Cices N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus. 2007;16:309-17. doi: 10.1177/0961203307077987

9. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22. doi: 10.1136/ard.2010.137216

10. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum. 2016;68(1):1-26.doi: 10.1002/art.39480

11. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. doi: 10.1093/cid/cit684

12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725-9. doi: 10.1002/art.1780400928

13. Petri M, Orbai A-M, Alarcon GS, et al. Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473

14. Krasselt M, Baerwald C, Seifert O. Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic. Z Rheumatol. 2017 Dec 13. doi: 10.1007/s00393-017-0410-5

15. Lawson EF, Trupin L, von Scheven E, et al. Reasons for failure to obtain influenza and pneumococcal vaccines among immunosup-pressed individuals with systemic lupus erythematosus. Arthritis Rheum. 2013;65(10 Suppl):362.

16. Ditto MC, Batticiotto A, Gerardi MC, et al. Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study. Arthritis Rheum. 2017;69(Suppl 10):S396-7.

17. Wise K, Barbar-Smiley F, Lemle S, et al. Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus. Arthritis Rheum. 2017;69(Suppl 10):S2924-5.

18. Brocq O, Acquacalda E, Berthier F, et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Joint Bone Spine. 2016;83(2):155-9. doi: 10.1016/j.jbspin.2015.11.005

19. Puges M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology. 2016;55(9):1664-72. doi: 10.1093/rheumatology/kew211

20. Chang CC, Chang YS, Chen WS, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study. Sci Rep. 2016;6:37817. doi: 10.1038/srep37817

21. Bü hler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015 Jul 28;145:w14159. doi: 10.4414/smw.2015.14159

22. Kozlov RS. Modern possibilities of specific prevention of pneumococcal infections. Klinicheskaya Mikrobiologiya i Antimikrobnaya Himioterapiya. 2002;4(1):61-9 (In Russ.)

23. Naumtseva MS, Belov BS, Aleksandrova EN, et al. Immunogenicity and safety of 23-valent polysaccharide pneumococcal vaccine in patients with rheumatoid arthritis: Results of a two-year follow-up study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):674-80 (In Russ.)]. doi: 10.14412/1995-4484-2016-674-680

24. Immunization with polysaccharide polyvalent vaccine for the prevention of pneumococcal infection: Method. recommendations (approved by Rospotrebnadzor on 08.02.2008 No. 01 / 816-8-34). Byulleten'Normativnykh i Metodicheskikh Dokumentov Gossanepidnadzora. 2008;(1) (In Russ.)

25. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA) // Bacterial Respiratory Pathogen Reference Laboratory: сайт. Режим доступа: http://www.vaccine.uab.edu/ELISA%20protocol.pdf. Загл. с экрана.

26. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34(2):147-53. doi: 10.1086/338043

27. Burmester GR, Charles-Schoeman C, Isaacs JD, et al. Tofacitinib, an oral Janus kinase inhibitor: safety comparisonin patients with rheumatoid arthritis and an inadequate response to nonbiologic or biologic disease modifying anti-rheumatic drugs. Arthritis Rheum. 2013;65(10 Suppl):192. doi: 10.1136/annrheumdis-2013-eular.766

28. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor , and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26. doi: 10.1002/acr.22246

29. Crnkic Kapetanovic M, Saxne T, Jö nsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi: 10.1186/ar4358

30. Binder M, Otto F, Mertelsmann R, et al. The epitope recognized by rituximab. Blood. 2006;108(6):1975-8. doi: 10.1182/blood-2006-04-014639

31. Maslyanskij AL, Mazurov VI, Zotkin EG. Anti-B-cell therapy for autoimmune diseases. Medicinskaya Immunologiya. 2007;9(1):15-34 (In Russ.)

32. Centers for Disease Control (CDC). Pneumococcal polysaccha-ride vaccine. Morb Mortal Wkly Rep. 1989;38(5):64-8, 73-6.

33. Mel'nichenko PI, Mosyagin VD, Zhogolev SD. The use of pneumococcal vaccine «Pnevmo 23» for the prevention of infections of the respiratory tract and ENT organs in military personnel. Vakcinaciya. Novosti Vakcinoprofilaktiki. 2003;(5):9-11 (In Russ.)